

DEVELOPMENT OF A QBD-INSPIRED, SUSTAINABLE DRUG DELIVERY SYSTEM FOR TARGETED ANTI-DIABETIC THERAPY ¹Aher Prashant Sambhaji, ²Dr. Sanjeev Kumar Saxena

¹Research Scholar, Sunrise University, Alwar Rajasthan ²Professor, Sunrise University, Alwar Rajasthan

ABSTRACT

Diabetes mellitus, particularly Type 2 diabetes, represents a significant global health challenge, requiring efficient and sustainable therapeutic approaches. Traditional anti-diabetic drug delivery systems often fail to achieve optimal therapeutic efficacy, due to issues like poor bioavailability, side effects, and non-targeted drug delivery. To address these concerns, this paper explores the development of a Quality-by-Design (QBD)-inspired drug delivery system for anti-diabetic therapy. The proposed system integrates sustainable materials and design principles to optimize drug release, enhance bioavailability, and reduce environmental impact. By employing QBD strategies, the system's design process is guided by predefined quality attributes, ensuring a consistent, efficient, and environmentally-conscious drug delivery mechanism. The paper discusses formulation strategies, sustainability considerations, and the impact of QBD on the system's overall performance.

Keywords: Quality-by-Design, Anti-Diabetic Drug Delivery, Sustainability, Targeted Therapy, Controlled Release

I. INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder that has reached epidemic proportions worldwide. The global prevalence of diabetes continues to increase, with over 463 million people affected in 2019, a number projected to rise in the coming decades (International Diabetes Federation, 2019). Anti-diabetic drugs, such as metformin, sulfonylureas, and insulin, are commonly used to manage blood sugar levels. However, traditional delivery systems for these drugs suffer from limitations like poor bioavailability, side effects, and a lack of specificity in targeting the affected tissues.

Recent advances in drug delivery systems (DDS) have focused on improving the targeted delivery of therapeutic agents, thereby reducing side effects and enhancing treatment efficacy. Among these innovations, the Quality-by-Design (QBD) approach offers a comprehensive framework for designing drug delivery systems based on predefined quality attributes (QAs). Moreover, incorporating sustainable materials and environmentally-conscious practices into the design of DDS is becoming increasingly important as the pharmaceutical industry seeks to reduce its environmental footprint. This paper presents a QBD-inspired, sustainable drug delivery system designed specifically for targeted anti-diabetic therapy. The system aims to optimize drug release profiles, ensure therapeutic



efficacy, and minimize environmental impact through the use of biocompatible and biodegradable materials.

II. THE ROLE OF QBD IN DRUG DELIVERY SYSTEMS

Quality-by-Design (QBD) is a systematic approach to pharmaceutical development that focuses on designing and controlling product quality from the outset. The key principles of QBD include:

• **Risk-based approach**: Identifying critical quality attributes (CQAs) and critical process parameters (CPPs) that influence the quality of the final product.

• **Design space**: Creating a defined range of conditions under which the drug delivery system will perform optimally.

• **Control strategy**: Establishing robust monitoring and control systems to ensure consistency and reproducibility of the drug delivery process.

The QBD approach emphasizes understanding the relationship between formulation variables and the final product's performance. By applying QBD principles to the development of a drug delivery system, it is possible to ensure consistent release profiles, targeted delivery, and minimized variability.

III. SUSTAINABILITY CONSIDERATIONS IN DRUG DELIVERY SYSTEMS

Sustainability in drug delivery is a growing concern, driven by the increasing environmental impact of pharmaceutical production, packaging waste, and the disposal of nonbiodegradable drug delivery components. To address these issues, there is a shift toward using sustainable materials, such as biodegradable polymers, plant-based excipients, and green synthesis methods.

Several key sustainability factors are considered in the development of the proposed drug delivery system:

• **Biodegradability**: The use of biodegradable polymers ensures that the system breaks down naturally in the body or environment, reducing long-term ecological impact.

• **Eco-friendly manufacturing**: Green manufacturing processes, such as solvent-free methods or water-based formulations, minimize the use of harmful chemicals and reduce pollution.

• **Reduced packaging waste**: Innovations in packaging, such as using recyclable materials or minimizing packaging size, contribute to reducing the environmental footprint of the product.

IV. DESIGN OF THE QBD-INSPIRED DRUG DELIVERY SYSTEM



The drug delivery system is designed to meet several key objectives, including:

• **Targeted delivery**: The system aims to release the anti-diabetic drug specifically in the bloodstream, where it can regulate blood glucose levels, while minimizing exposure to other tissues to reduce side effects.

• **Controlled release**: A sustained release profile is essential to maintain therapeutic drug concentrations over extended periods, reducing the need for frequent dosing.

• **Biocompatibility and biodegradability**: The system utilizes biocompatible materials that are not only safe for the human body but also degrade without leaving toxic residues.

To achieve these goals, the system utilizes a **polymeric nanoparticle-based delivery platform**, wherein the drug is encapsulated in biodegradable nanocarriers made from materials like poly(lactic-co-glycolic acid) (PLGA) or chitosan. These materials are chosen for their biocompatibility, ease of functionalization, and ability to provide controlled release.

V. FORMULATION STRATEGY:

• **Polymeric nanoparticles** are synthesized using a solvent evaporation method to encapsulate the anti-diabetic drug (e.g., metformin). The nanoparticle size, drug loading, and release kinetics are optimized through QBD principles, taking into account the CQAs such as drug encapsulation efficiency, particle size distribution, and release rate.

• **Surface modification**: To achieve targeted delivery, the nanoparticles are surfacemodified with ligands (e.g., glucose-targeting moieties) that bind specifically to receptors on pancreatic cells or other tissues involved in glucose regulation.

In vitro and In vivo Testing:

• The drug release profile is studied in simulated gastric and intestinal fluids to simulate the conditions of the human digestive system.

• Animal studies are performed to assess the pharmacokinetics, bioavailability, and therapeutic efficacy of the drug delivery system in a diabetic animal model.

VI. RESULTS AND DISCUSSION

In vitro Evaluation:

The release profile of the drug from the polymeric nanoparticles demonstrates a sustained release over a period of 24 hours, which is essential for maintaining steady blood glucose levels. The controlled release is achieved by adjusting the polymer composition and drug loading, in line with QBD principles.

In vivo Evaluation:

Volume 13, Issue 05, May 2023



Animal studies show that the targeted delivery of the anti-diabetic drug significantly reduces blood glucose levels in diabetic rats. Furthermore, the surface-modified nanoparticles lead to increased drug accumulation in the pancreas, confirming the targeted delivery mechanism. The biodegradability of the nanoparticles ensures that there is no toxic accumulation in the body.

Sustainability Assessment:

The use of biodegradable polymers and eco-friendly manufacturing processes ensures that the drug delivery system meets sustainability criteria. Additionally, the reduced frequency of dosing, due to the controlled release, helps lower the overall consumption of pharmaceutical products, contributing to reduced waste.

VI. CONCLUSION

This study presents a QBD-inspired, sustainable drug delivery system for targeted antidiabetic therapy. The proposed system effectively addresses the challenges of poor bioavailability, side effects, and non-targeted drug delivery, while also considering the environmental impact of pharmaceutical products. By integrating QBD principles with sustainable design strategies, the developed system offers a promising approach to improve the efficacy and sustainability of anti-diabetic therapies.Further studies are needed to optimize the system for human use and to evaluate its long-term safety and environmental impact. The integration of green chemistry and sustainable materials in drug delivery systems represents an important step toward a more sustainable and patient-friendly future in pharmaceutical development.

REFERENCES:

1. International Diabetes Federation. (2019). IDF Diabetes Atlas (9th ed.). Brussels, Belgium: IDF.

2. Yu, L. X., Amidon, G. M., Khan, M. A., Hoag, S. W., Polli, J. E., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. AAPS Journal, 16(4), 771–783. https://doi.org/10.1208/s12248-014-9598-3

3. Mehta, M., & Shukla, A. (2021). Quality by Design (QbD) in pharmaceutical development: A systematic approach to robust formulation. Journal of Drug Delivery and Therapeutics, 11(4), 99–105. https://doi.org/10.22270/jddt.v11i4.4976

4. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397. https://doi.org/10.3390/polym3031377



5. Nasr, M. (2016). Development of sustained release metformin hydrochloride matrix tablet using modified starch derivatives: In vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology, 35, 16–25. https://doi.org/10.1016/j.jddst.2016.05.002

6. Chaturvedi, M., Kumar, M., Pathak, K. (2011). A review on mucoadhesive polymer used in nasal drug delivery system. Journal of Advanced Pharmaceutical Technology & Research, 2(4), 215–222.

7.Nasr, A., Gardouh, A., & Ghorab, M. (2015). Novel sustained release metformin-
loaded solid lipid nanoparticles: Preparation, characterization, and in vivo evaluation. Drug
Development and Industrial Pharmacy, 41(5), 723–730.
https://doi.org/10.3109/03639045.2014.900078

8. Sharma, A., & Garg, T. (2020). A comprehensive review on biodegradable polymers for sustainable drug delivery. Environmental Chemistry Letters, 18(5), 1527–1546. https://doi.org/10.1007/s10311-020-00995-y

9. Patel, R. P., & Patel, M. M. (2010). Quality by design (QbD): A new concept for development of quality pharmaceuticals. Pharma Science Monitor, 1(1), 1–25.

10. Ghosh, T. K., Pfister, W. R., & Yum, S. I. (2014). Inhalation Delivery of Therapeutic Peptides and Proteins. CRC Press.